Lantern Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lantern Pharma, Inc. - overview
Established
2013
Location
Dallas, TX, US
Primary Industry
Biotechnology
About
Based in Texas, US, and founded in 2013 Lantern Pharma, Inc. is a biotechnology company that provides oncology therapeutics using artificial intelligence, genomics, and machine learning to identify and developed cancer therapies. The company becomes a publicly listed company on the NASDAQ stock exchange, In June 2020. The company has approximately 18 employees.
Lantern Pharma, Inc. is a biotechnology company. It is focused on leveraging artificial intelligence machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves three small molecule drug candidates namely LP-100, LP-184, and LP-300.
The company generates revenue by offering the developed therapies to pharmaceutical companies. The company’s long-term objective is to identify more oncology-specific preclinical points towards the development of the RADR platform.
Current Investors
Health Wildcatters, Green Park & Golf Ventures, Bios Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Bioinformatics, Oncology/Cancer Treatment, Pharmaceutical Research & Development, Analytics & Performance Software
Website
www.lanternpharma.com
Verticals
Artificial Intelligence
Company Stage
Mature
Total Amount Raised
Subscriber access only
Lantern Pharma, Inc. - financials
| Fiscal Year Ended | Dec 30, 2018 | Dec 30, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (1,700,000) | (2,400,000) | - | (12,444,241) | (14,340,802) | - | - | - |
| Operating Income (USD) | (1,700,000) | (2,400,000) | - | (12,591,508) | (14,432,753) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - |
| NET Income (USD) | (1,700,000) | (2,400,000) | (5,908,190) | (12,363,029) | (14,259,946) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - |
Lantern Pharma, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.